Back to Search Start Over

Disease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study.

Authors :
Zuhur SS
Ozturk BO
Keskin U
Uysal S
Hacioglu A
Avci U
Karsli S
Andac B
Ozbay UN
Kilinc F
Erol S
Catak M
Sodan H
Pekkolay Z
Burhan S
Akbaba G
Ates C
Yorulmaz G
Tekin S
Topcu B
Tuna MM
Kadioglu P
Gonen MS
Karaca Z
Ciftci S
Celik M
Guldiken S
Tuzun D
Altuntas Y
Akturk M
Niyazoglu M
Cinar N
Gul OO
Kebapci MN
Akalin A
Bayraktaroglu T
Elbuken G
Source :
Endocrine [Endocrine] 2024 Sep; Vol. 85 (3), pp. 1300-1309. Date of Electronic Publication: 2024 Apr 03.
Publication Year :
2024

Abstract

Purpose: Despite several factors that may have been associated with poor disease-free survival (DFS) in patients with medullary thyroid carcinoma (MTC), only a few studies have evaluated the prognostic factors affecting DFS in MTC patients. Therefore, this study evaluated the prognostic factors affecting DFS, in a large number of patients with MTC.<br />Methods: Patients treated for MTC were retrospectively analyzed. Patients were stratified as having persistent/recurrent disease and no evidence of disease (NOD) at the last follow-up. The factors affecting DFS after the initial therapy and during the follow-up period were investigated.<br />Results: This study comprised 257 patients [females 160 (62.3%), hereditary disease 48 (18.7%), with a mean follow-up time of 66.8 ± 48.5 months]. Persistent/recurrent disease and NOD were observed in 131 (51%) and 126 (49%) patients, respectively. In multivariate analysis, age > 55 (HR: 1.65, p = 0.033), distant metastasis (HR: 2.41, p = 0.035), CTN doubling time (HR: 2.7, p = 0.031), and stage III vs. stage II disease (HR 3.02, p = 0.048) were independent predictors of persistent/recurrent disease. Although 9 (8%) patients with an excellent response after the initial therapy experienced a structural recurrence, the absence of an excellent response was the strongest predictor of persistent/recurrent disease (HR: 5.74, p < 0.001).<br />Conclusions: The absence of an excellent response after initial therapy is the strongest predictor of a worse DFS. However, a significant proportion of patients who achieve an excellent response could experience a structural recurrence. Therefore, careful follow-up of patients, including those achieving an excellent response is essential.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1559-0100
Volume :
85
Issue :
3
Database :
MEDLINE
Journal :
Endocrine
Publication Type :
Academic Journal
Accession number :
38570387
Full Text :
https://doi.org/10.1007/s12020-024-03809-0